Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and PK of [14C]Olmutinib in Healthy Males
NCT02722161Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olmutinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Mass balance recovery of [14C]-radioactivity in urine up to 7 weeks and Mass balance recovery of [14C]-radioactivity in faeces up to 7 weeks. Started Apr 2016; status: completed.
02
Drugs
olmutinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02722161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722161.